Craig Sauter, MD

Craig Sauter, MD, discusses where BTK inhibitors could fit into the frontline treatment landscape for patients with central nervous system lymphoma and research aiming to address other unmet needs for this patient population.

Craig Sauter, MD, discusses prominent questions surrounding new and emerging therapies in the treatment of patients with hematologic malignancies.

Craig Sauter, MD, discusses important considerations regarding the use of pembrolizumab after autologous stem cell transplant in T-cell non-Hodgkin lymphoma.

Craig Sauter, MD, discusses the investigation of pembrolizumab given after stem cell transplant in T-cell non-Hodgkin lymphoma.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss recent data showing that the CAR T-cell production can be shortened.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss potential directions for CAR T-cell therapy in lymphomas.

Brian T. Hill, MD, PhD, and Craig Sauter, MD, discuss the promise of allogeneic CAR T-cell products.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, address the issue of financial toxicity in CAR T-cell therapy.

Craig Sauter, MD, discusses the differences between off-the-shelf and autologous chimeric antigen receptor T-cell products in patients with hematologic malignancies.

Craig Sauter, MD, discusses the anecdotal observational data in real-world patients with hematologic malignancies who received chimeric antigen receptor T-cell therapy.